Pfizer Inc (PFE) 31.99 $PFE
This is Incredibly Good News for Breast Cancer Survivors
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 11:08AM CST
Source: Komen Austin via Flickr . There are few, if any, medical diagnoses in life that are scarier than cancer. Based on data from the Centers for Disease Control and Prevention, cancer is now the second-leading cause of death in the United...
PFE: 31.99 (+0.32), GALE: 1.69 (+0.02)
Is Obamacare Failing Where It's Needed Most?
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 8:52AM CST
Source: White House on Flickr. It's been about three weeks since the online marketplaces associated with the Affordable Care Act, best known as Obamacare, reopened, and the good news is that things are running smoothly . Unlike last year, which...
ANTM: 127.91 (+0.27), MDT: 75.04 (+1.10), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Most active New York Stock Exchange-traded stocks
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KOG: 6.56 (-0.39), KMI: 41.12 (-0.34), F: 15.70 (-0.11), RF: 10.37 (+0.26), PFE: 31.99 (+0.32), AEO: 11.91 (-1.90), HAL: 40.37 (-0.37), BAC: 17.68 (+0.47), SDRL: 12.32 (-0.01)
Final Glance: Pharmaceuticals companies
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
What Eli Lilly Can Do To Keep Its Amazing Rally Going In 2015
Bob Ciura - at Seeking Alpha - Fri Dec 05, 4:07PM CST
JNJ: 108.51 (+0.95), PFE: 31.99 (+0.32), AZN: 73.72 (-0.22), LLY: 71.85 (-0.53)
Look for Shares of Pfizer to Potentially Pullback after Yesterday's 1.01% Rise
Comtex SmarTrend(R) - Fri Dec 05, 3:41PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $31.60 to a high of $32.15. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $31.82 on volume of 24.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 31.99 (+0.32)
Watch for Pfizer to Potentially Pullback After Gaining 1.01% Yesterday
Comtex SmarTrend(R) - Fri Dec 05, 3:41PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $31.60 to a high of $32.15. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $31.82 on volume of 24.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 31.99 (+0.32)
Will Someone Take GlaxoSmithKline Out Of Its Misery?
Dana Blankenhorn - at Seeking Alpha - Fri Dec 05, 3:11PM CST
PFE: 31.99 (+0.32), AZN: 73.72 (-0.22), GSK: 46.04 (+0.15), NVS: 95.83 (+0.06)
Midday Glance: Pharmaceuticals companies
AP - Fri Dec 05, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Early Glance: Pharmaceuticals companies
AP - Fri Dec 05, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
Business Wire - Thu Dec 04, 3:00PM CST
The board of directors of Tenet Healthcare Corporation (NYSE:THC) has appointed Freda C. Lewis-Hall, M.D., executive vice president and chief medical officer of Pfizer Inc., as a new independent director. Dr. Lewis-Hall becomes the board's tenth member.
THC: 51.79 (+3.37), PFE: 31.99 (+0.32)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - Thu Dec 04, 2:57PM CST
MMLP: 32.89 (-0.57), HCP: 44.30 (-1.27), CAG: 36.99 (+0.48), PFE: 31.99 (+0.32), ED: 63.26 (-0.81), BBEP: 10.29 (-0.71), O: 45.51 (-0.65), BMY: 60.65 (+1.76), DRI: 58.52 (+0.67), T: 33.94 (+0.03), STON: 26.79 (+0.12), JNJ: 108.51 (+0.95), CBRL: 131.73 (+2.95), SUI: 58.92 (+0.37), S: 4.85 (-0.01), OHI: 37.93 (-0.49), FUN: 45.96 (-0.06), LINE: 16.52 (-0.53), EPR: 56.44 (-0.31), VZ: 48.61 (-0.17)
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
PR Newswire Europe - Thu Dec 04, 10:40AM CST
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavoured. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief (PEPFAR) programme means the formulations meet all of the agency's quality, safety and efficacy standards.
PFE: 31.99 (+0.32), MYL: 58.41 (+0.18), GSK: 46.04 (+0.15)
This is Incredibly Good News for Breast Cancer Survivors
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 11:08AM CST
Source: Komen Austin via Flickr . There are few, if any, medical diagnoses in life that are scarier than cancer. Based on data from the Centers for Disease Control and Prevention, cancer is now the second-leading cause of death in the United...
PFE: 31.99 (+0.32), GALE: 1.69 (+0.02)
Is Obamacare Failing Where It's Needed Most?
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 8:52AM CST
Source: White House on Flickr. It's been about three weeks since the online marketplaces associated with the Affordable Care Act, best known as Obamacare, reopened, and the good news is that things are running smoothly . Unlike last year, which...
ANTM: 127.91 (+0.27), MDT: 75.04 (+1.10), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Most active New York Stock Exchange-traded stocks
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KOG: 6.56 (-0.39), KMI: 41.12 (-0.34), F: 15.70 (-0.11), RF: 10.37 (+0.26), PFE: 31.99 (+0.32), AEO: 11.91 (-1.90), HAL: 40.37 (-0.37), BAC: 17.68 (+0.47), SDRL: 12.32 (-0.01)
Final Glance: Pharmaceuticals companies
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
What Eli Lilly Can Do To Keep Its Amazing Rally Going In 2015
Bob Ciura - at Seeking Alpha - Fri Dec 05, 4:07PM CST
JNJ: 108.51 (+0.95), PFE: 31.99 (+0.32), AZN: 73.72 (-0.22), LLY: 71.85 (-0.53)
Look for Shares of Pfizer to Potentially Pullback after Yesterday's 1.01% Rise
Comtex SmarTrend(R) - Fri Dec 05, 3:41PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $31.60 to a high of $32.15. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $31.82 on volume of 24.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 31.99 (+0.32)
Watch for Pfizer to Potentially Pullback After Gaining 1.01% Yesterday
Comtex SmarTrend(R) - Fri Dec 05, 3:41PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $31.60 to a high of $32.15. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $31.82 on volume of 24.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 31.99 (+0.32)
Will Someone Take GlaxoSmithKline Out Of Its Misery?
Dana Blankenhorn - at Seeking Alpha - Fri Dec 05, 3:11PM CST
PFE: 31.99 (+0.32), AZN: 73.72 (-0.22), GSK: 46.04 (+0.15), NVS: 95.83 (+0.06)
Midday Glance: Pharmaceuticals companies
AP - Fri Dec 05, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Early Glance: Pharmaceuticals companies
AP - Fri Dec 05, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.51 (+0.95), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), BMY: 60.65 (+1.76)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
Business Wire - Thu Dec 04, 3:00PM CST
The board of directors of Tenet Healthcare Corporation (NYSE:THC) has appointed Freda C. Lewis-Hall, M.D., executive vice president and chief medical officer of Pfizer Inc., as a new independent director. Dr. Lewis-Hall becomes the board's tenth member.
THC: 51.79 (+3.37), PFE: 31.99 (+0.32)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - Thu Dec 04, 2:57PM CST
MMLP: 32.89 (-0.57), HCP: 44.30 (-1.27), CAG: 36.99 (+0.48), PFE: 31.99 (+0.32), ED: 63.26 (-0.81), BBEP: 10.29 (-0.71), O: 45.51 (-0.65), BMY: 60.65 (+1.76), DRI: 58.52 (+0.67), T: 33.94 (+0.03), STON: 26.79 (+0.12), JNJ: 108.51 (+0.95), CBRL: 131.73 (+2.95), SUI: 58.92 (+0.37), S: 4.85 (-0.01), OHI: 37.93 (-0.49), FUN: 45.96 (-0.06), LINE: 16.52 (-0.53), EPR: 56.44 (-0.31), VZ: 48.61 (-0.17)
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
PR Newswire Europe - Thu Dec 04, 10:40AM CST
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavoured. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief (PEPFAR) programme means the formulations meet all of the agency's quality, safety and efficacy standards.
PFE: 31.99 (+0.32), MYL: 58.41 (+0.18), GSK: 46.04 (+0.15)
